nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—ABCG2—Leflunomide—systemic scleroderma	0.165	0.276	CbGbCtD
Mitoxantrone—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.102	0.17	CbGbCtD
Mitoxantrone—ABCB1—Lisinopril—systemic scleroderma	0.0625	0.104	CbGbCtD
Mitoxantrone—ABCC1—Methotrexate—systemic scleroderma	0.0613	0.102	CbGbCtD
Mitoxantrone—ABCB1—Captopril—systemic scleroderma	0.0468	0.078	CbGbCtD
Mitoxantrone—ABCG2—Methotrexate—systemic scleroderma	0.041	0.0683	CbGbCtD
Mitoxantrone—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0369	0.0614	CbGbCtD
Mitoxantrone—ABCB1—Prednisone—systemic scleroderma	0.0295	0.0491	CbGbCtD
Mitoxantrone—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0221	0.0368	CbGbCtD
Mitoxantrone—CYP3A4—Prednisone—systemic scleroderma	0.0177	0.0294	CbGbCtD
Mitoxantrone—ABCB1—Methotrexate—systemic scleroderma	0.0148	0.0246	CbGbCtD
Mitoxantrone—BTK—connective tissue—systemic scleroderma	0.00417	0.0812	CbGeAlD
Mitoxantrone—SLC47A2—digestive system—systemic scleroderma	0.00399	0.0778	CbGeAlD
Mitoxantrone—SLC47A2—tendon—systemic scleroderma	0.0038	0.074	CbGeAlD
Mitoxantrone—PIM1—connective tissue—systemic scleroderma	0.00361	0.0703	CbGeAlD
Mitoxantrone—PIM1—skin of body—systemic scleroderma	0.00326	0.0635	CbGeAlD
Mitoxantrone—BTK—tendon—systemic scleroderma	0.00286	0.0558	CbGeAlD
Mitoxantrone—PIM1—digestive system—systemic scleroderma	0.00261	0.0508	CbGeAlD
Mitoxantrone—BTK—TSLP Signaling Pathway—TNFSF4—systemic scleroderma	0.00256	0.131	CbGpPWpGaD
Mitoxantrone—BTK—lung—systemic scleroderma	0.00251	0.049	CbGeAlD
Mitoxantrone—PIM1—tendon—systemic scleroderma	0.00248	0.0484	CbGeAlD
Mitoxantrone—PIM1—lung—systemic scleroderma	0.00218	0.0424	CbGeAlD
Mitoxantrone—PIM1—GMCSF-mediated signaling events—IRF8—systemic scleroderma	0.002	0.102	CbGpPWpGaD
Mitoxantrone—TOP2A—tendon—systemic scleroderma	0.00146	0.0284	CbGeAlD
Mitoxantrone—CYP1B1—connective tissue—systemic scleroderma	0.00142	0.0276	CbGeAlD
Mitoxantrone—SLC47A1—digestive system—systemic scleroderma	0.0014	0.0272	CbGeAlD
Mitoxantrone—SLC47A1—tendon—systemic scleroderma	0.00133	0.0259	CbGeAlD
Mitoxantrone—CYP1B1—smooth muscle tissue—systemic scleroderma	0.0013	0.0253	CbGeAlD
Mitoxantrone—CYP1B1—skin of body—systemic scleroderma	0.00128	0.0249	CbGeAlD
Mitoxantrone—TOP2A—lung—systemic scleroderma	0.00128	0.0249	CbGeAlD
Mitoxantrone—SLC47A1—lung—systemic scleroderma	0.00117	0.0227	CbGeAlD
Mitoxantrone—PIM1—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.00114	0.0586	CbGpPWpGaD
Mitoxantrone—BTK—Antigen activates B Cell Receptor (BCR) leading to generation of second messengers—BLK—systemic scleroderma	0.00107	0.0547	CbGpPWpGaD
Mitoxantrone—CYP1B1—digestive system—systemic scleroderma	0.00102	0.02	CbGeAlD
Mitoxantrone—ABCB1—blood vessel—systemic scleroderma	0.00102	0.0198	CbGeAlD
Mitoxantrone—CYP1B1—tendon—systemic scleroderma	0.000974	0.019	CbGeAlD
Mitoxantrone—ABCC1—tendon—systemic scleroderma	0.000876	0.0171	CbGeAlD
Mitoxantrone—CYP1B1—lung—systemic scleroderma	0.000855	0.0167	CbGeAlD
Mitoxantrone—BTK—Class I PI3K signaling events—BLK—systemic scleroderma	0.000853	0.0437	CbGpPWpGaD
Mitoxantrone—PIM1—GMCSF-mediated signaling events—CCL2—systemic scleroderma	0.000815	0.0418	CbGpPWpGaD
Mitoxantrone—BTK—TSLP Signaling Pathway—STAT4—systemic scleroderma	0.000784	0.0402	CbGpPWpGaD
Mitoxantrone—ABCC1—lung—systemic scleroderma	0.000769	0.015	CbGeAlD
Mitoxantrone—BTK—Regulation of actin dynamics for phagocytic cup formation—CD247—systemic scleroderma	0.000763	0.0391	CbGpPWpGaD
Mitoxantrone—BTK—BCR signaling pathway—CSK—systemic scleroderma	0.000713	0.0365	CbGpPWpGaD
Mitoxantrone—CYP2E1—digestive system—systemic scleroderma	0.00066	0.0129	CbGeAlD
Mitoxantrone—ABCG2—lung—systemic scleroderma	0.000637	0.0124	CbGeAlD
Mitoxantrone—CYP2E1—tendon—systemic scleroderma	0.000628	0.0122	CbGeAlD
Mitoxantrone—BTK—Fcgamma receptor (FCGR) dependent phagocytosis—CD247—systemic scleroderma	0.000576	0.0295	CbGpPWpGaD
Mitoxantrone—CYP2E1—lung—systemic scleroderma	0.000551	0.0107	CbGeAlD
Mitoxantrone—CYP3A4—digestive system—systemic scleroderma	0.000531	0.0104	CbGeAlD
Mitoxantrone—TOP2A—Methyltestosterone—Prednisone—systemic scleroderma	0.000511	1	CbGdCrCtD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.000461	0.0236	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.000415	0.0213	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000391	0.02	CbGpPWpGaD
Mitoxantrone—ABCB1—digestive system—systemic scleroderma	0.000376	0.00733	CbGeAlD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.00037	0.0189	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.00035	0.0179	CbGpPWpGaD
Mitoxantrone—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IL1A—systemic scleroderma	0.000343	0.0176	CbGpPWpGaD
Mitoxantrone—CYP1B1—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.00034	0.0174	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000319	0.0164	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—MMP9—systemic scleroderma	0.000318	0.0163	CbGpPWpGaD
Mitoxantrone—ABCB1—lung—systemic scleroderma	0.000314	0.00612	CbGeAlD
Mitoxantrone—TOP2A—Circadian rythm related genes—TOP1—systemic scleroderma	0.000307	0.0157	CbGpPWpGaD
Mitoxantrone—Dyspepsia—Leflunomide—systemic scleroderma	0.000294	0.000896	CcSEcCtD
Mitoxantrone—Vomiting—Mometasone—systemic scleroderma	0.000294	0.000894	CcSEcCtD
Mitoxantrone—Sweating increased—Prednisone—systemic scleroderma	0.000292	0.000889	CcSEcCtD
Mitoxantrone—Feeling abnormal—Azathioprine—systemic scleroderma	0.000292	0.000888	CcSEcCtD
Mitoxantrone—Rash—Mometasone—systemic scleroderma	0.000291	0.000886	CcSEcCtD
Mitoxantrone—Asthenia—Captopril—systemic scleroderma	0.000291	0.000886	CcSEcCtD
Mitoxantrone—Dermatitis—Mometasone—systemic scleroderma	0.000291	0.000885	CcSEcCtD
Mitoxantrone—Decreased appetite—Leflunomide—systemic scleroderma	0.000291	0.000884	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000291	0.000884	CcSEcCtD
Mitoxantrone—Confusional state—Lisinopril—systemic scleroderma	0.00029	0.000882	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000289	0.000881	CcSEcCtD
Mitoxantrone—Headache—Mometasone—systemic scleroderma	0.000289	0.000881	CcSEcCtD
Mitoxantrone—Fatigue—Leflunomide—systemic scleroderma	0.000288	0.000877	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000287	0.000874	CcSEcCtD
Mitoxantrone—Oedema—Lisinopril—systemic scleroderma	0.000287	0.000874	CcSEcCtD
Mitoxantrone—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000286	0.000872	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000286	0.000871	CcSEcCtD
Mitoxantrone—Pain—Leflunomide—systemic scleroderma	0.000286	0.00087	CcSEcCtD
Mitoxantrone—Constipation—Leflunomide—systemic scleroderma	0.000286	0.00087	CcSEcCtD
Mitoxantrone—Infection—Lisinopril—systemic scleroderma	0.000285	0.000869	CcSEcCtD
Mitoxantrone—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000285	0.000867	CcSEcCtD
Mitoxantrone—PIM1—Ectoderm Differentiation—CCL2—systemic scleroderma	0.000284	0.0146	CbGpPWpGaD
Mitoxantrone—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000284	0.000865	CcSEcCtD
Mitoxantrone—Somnolence—Mycophenolic acid—systemic scleroderma	0.000283	0.000863	CcSEcCtD
Mitoxantrone—Shock—Lisinopril—systemic scleroderma	0.000283	0.00086	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000281	0.000856	CcSEcCtD
Mitoxantrone—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000281	0.000854	CcSEcCtD
Mitoxantrone—Neutropenia—Prednisone—systemic scleroderma	0.00028	0.000854	CcSEcCtD
Mitoxantrone—Tachycardia—Lisinopril—systemic scleroderma	0.00028	0.000853	CcSEcCtD
Mitoxantrone—Abdominal pain—Azathioprine—systemic scleroderma	0.00028	0.000852	CcSEcCtD
Mitoxantrone—Body temperature increased—Azathioprine—systemic scleroderma	0.00028	0.000852	CcSEcCtD
Mitoxantrone—Skin disorder—Lisinopril—systemic scleroderma	0.000279	0.000849	CcSEcCtD
Mitoxantrone—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000278	0.000846	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000278	0.000845	CcSEcCtD
Mitoxantrone—Diarrhoea—Captopril—systemic scleroderma	0.000277	0.000845	CcSEcCtD
Mitoxantrone—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000277	0.000844	CcSEcCtD
Mitoxantrone—Erectile dysfunction—Prednisone—systemic scleroderma	0.000276	0.000841	CcSEcCtD
Mitoxantrone—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000276	0.00084	CcSEcCtD
Mitoxantrone—Feeling abnormal—Leflunomide—systemic scleroderma	0.000275	0.000838	CcSEcCtD
Mitoxantrone—Fatigue—Mycophenolic acid—systemic scleroderma	0.000275	0.000837	CcSEcCtD
Mitoxantrone—Nausea—Mometasone—systemic scleroderma	0.000274	0.000835	CcSEcCtD
Mitoxantrone—Anorexia—Lisinopril—systemic scleroderma	0.000274	0.000833	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000273	0.000832	CcSEcCtD
Mitoxantrone—Weight increased—Prednisone—systemic scleroderma	0.000273	0.000831	CcSEcCtD
Mitoxantrone—Constipation—Mycophenolic acid—systemic scleroderma	0.000273	0.00083	CcSEcCtD
Mitoxantrone—Pain—Mycophenolic acid—systemic scleroderma	0.000273	0.00083	CcSEcCtD
Mitoxantrone—Weight decreased—Prednisone—systemic scleroderma	0.000271	0.000826	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Prednisone—systemic scleroderma	0.000271	0.000824	CcSEcCtD
Mitoxantrone—Cough—Mycophenolate mofetil—systemic scleroderma	0.000269	0.000819	CcSEcCtD
Mitoxantrone—Hypotension—Lisinopril—systemic scleroderma	0.000268	0.000817	CcSEcCtD
Mitoxantrone—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000267	0.000813	CcSEcCtD
Mitoxantrone—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000266	0.00081	CcSEcCtD
Mitoxantrone—Urticaria—Leflunomide—systemic scleroderma	0.000266	0.000808	CcSEcCtD
Mitoxantrone—Abdominal pain—Leflunomide—systemic scleroderma	0.000264	0.000804	CcSEcCtD
Mitoxantrone—Body temperature increased—Leflunomide—systemic scleroderma	0.000264	0.000804	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—BLK—systemic scleroderma	0.000264	0.0135	CbGpPWpGaD
Mitoxantrone—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000264	0.000803	CcSEcCtD
Mitoxantrone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000263	0.0008	CcSEcCtD
Mitoxantrone—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000263	0.000799	CcSEcCtD
Mitoxantrone—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000263	0.000799	CcSEcCtD
Mitoxantrone—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000263	0.000799	CcSEcCtD
Mitoxantrone—Myocardial infarction—Prednisone—systemic scleroderma	0.000262	0.000798	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000262	0.000797	CcSEcCtD
Mitoxantrone—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000262	0.000796	CcSEcCtD
Mitoxantrone—Hypersensitivity—Azathioprine—systemic scleroderma	0.000261	0.000794	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000261	0.000794	CcSEcCtD
Mitoxantrone—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000259	0.000789	CcSEcCtD
Mitoxantrone—Paraesthesia—Lisinopril—systemic scleroderma	0.000258	0.000785	CcSEcCtD
Mitoxantrone—Vomiting—Captopril—systemic scleroderma	0.000258	0.000785	CcSEcCtD
Mitoxantrone—Dyspnoea—Lisinopril—systemic scleroderma	0.000256	0.000779	CcSEcCtD
Mitoxantrone—Rash—Captopril—systemic scleroderma	0.000256	0.000778	CcSEcCtD
Mitoxantrone—Dermatitis—Captopril—systemic scleroderma	0.000255	0.000778	CcSEcCtD
Mitoxantrone—Somnolence—Lisinopril—systemic scleroderma	0.000255	0.000777	CcSEcCtD
Mitoxantrone—Headache—Captopril—systemic scleroderma	0.000254	0.000773	CcSEcCtD
Mitoxantrone—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000254	0.000772	CcSEcCtD
Mitoxantrone—Dyspepsia—Lisinopril—systemic scleroderma	0.000253	0.00077	CcSEcCtD
Mitoxantrone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000252	0.000767	CcSEcCtD
Mitoxantrone—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000252	0.000767	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000252	0.000766	CcSEcCtD
Mitoxantrone—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000252	0.000766	CcSEcCtD
Mitoxantrone—Infection—Mycophenolate mofetil—systemic scleroderma	0.00025	0.000761	CcSEcCtD
Mitoxantrone—Decreased appetite—Lisinopril—systemic scleroderma	0.00025	0.00076	CcSEcCtD
Mitoxantrone—Fatigue—Lisinopril—systemic scleroderma	0.000248	0.000754	CcSEcCtD
Mitoxantrone—Shock—Mycophenolate mofetil—systemic scleroderma	0.000248	0.000754	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000246	0.00075	CcSEcCtD
Mitoxantrone—Hypersensitivity—Leflunomide—systemic scleroderma	0.000246	0.00075	CcSEcCtD
Mitoxantrone—Constipation—Lisinopril—systemic scleroderma	0.000246	0.000748	CcSEcCtD
Mitoxantrone—Pain—Lisinopril—systemic scleroderma	0.000246	0.000748	CcSEcCtD
Mitoxantrone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000246	0.000748	CcSEcCtD
Mitoxantrone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000244	0.000744	CcSEcCtD
Mitoxantrone—Bradycardia—Prednisone—systemic scleroderma	0.000244	0.000744	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000243	0.000741	CcSEcCtD
Mitoxantrone—Diarrhoea—Azathioprine—systemic scleroderma	0.000242	0.000737	CcSEcCtD
Mitoxantrone—Haemoglobin—Prednisone—systemic scleroderma	0.000241	0.000735	CcSEcCtD
Mitoxantrone—Nausea—Captopril—systemic scleroderma	0.000241	0.000733	CcSEcCtD
Mitoxantrone—Haemorrhage—Prednisone—systemic scleroderma	0.00024	0.000731	CcSEcCtD
Mitoxantrone—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00024	0.00073	CcSEcCtD
Mitoxantrone—Asthenia—Leflunomide—systemic scleroderma	0.00024	0.00073	CcSEcCtD
Mitoxantrone—Pancytopenia—Methotrexate—systemic scleroderma	0.000238	0.000725	CcSEcCtD
Mitoxantrone—Feeling abnormal—Lisinopril—systemic scleroderma	0.000237	0.00072	CcSEcCtD
Mitoxantrone—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000235	0.000716	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000235	0.000715	CcSEcCtD
Mitoxantrone—Neutropenia—Methotrexate—systemic scleroderma	0.000234	0.000714	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000233	0.000709	CcSEcCtD
Mitoxantrone—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000231	0.000703	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000698	CcSEcCtD
Mitoxantrone—Asthenia—Mycophenolic acid—systemic scleroderma	0.000229	0.000696	CcSEcCtD
Mitoxantrone—Diarrhoea—Leflunomide—systemic scleroderma	0.000229	0.000696	CcSEcCtD
Mitoxantrone—Urticaria—Lisinopril—systemic scleroderma	0.000228	0.000695	CcSEcCtD
Mitoxantrone—Abdominal pain—Lisinopril—systemic scleroderma	0.000227	0.000691	CcSEcCtD
Mitoxantrone—Body temperature increased—Lisinopril—systemic scleroderma	0.000227	0.000691	CcSEcCtD
Mitoxantrone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000226	0.000688	CcSEcCtD
Mitoxantrone—Vomiting—Azathioprine—systemic scleroderma	0.000225	0.000685	CcSEcCtD
Mitoxantrone—Pneumonia—Methotrexate—systemic scleroderma	0.000225	0.000684	CcSEcCtD
Mitoxantrone—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000224	0.000683	CcSEcCtD
Mitoxantrone—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000224	0.000681	CcSEcCtD
Mitoxantrone—Drowsiness—Methotrexate—systemic scleroderma	0.000224	0.00068	CcSEcCtD
Mitoxantrone—Rash—Azathioprine—systemic scleroderma	0.000223	0.000679	CcSEcCtD
Mitoxantrone—Dermatitis—Azathioprine—systemic scleroderma	0.000223	0.000679	CcSEcCtD
Mitoxantrone—Headache—Azathioprine—systemic scleroderma	0.000222	0.000675	CcSEcCtD
Mitoxantrone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000674	CcSEcCtD
Mitoxantrone—Renal failure—Methotrexate—systemic scleroderma	0.00022	0.000669	CcSEcCtD
Mitoxantrone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000219	0.000666	CcSEcCtD
Mitoxantrone—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000218	0.000664	CcSEcCtD
Mitoxantrone—Stomatitis—Methotrexate—systemic scleroderma	0.000218	0.000663	CcSEcCtD
Mitoxantrone—Conjunctivitis—Methotrexate—systemic scleroderma	0.000217	0.000661	CcSEcCtD
Mitoxantrone—Pain—Mycophenolate mofetil—systemic scleroderma	0.000215	0.000655	CcSEcCtD
Mitoxantrone—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000215	0.000655	CcSEcCtD
Mitoxantrone—Arrhythmia—Prednisone—systemic scleroderma	0.000214	0.000653	CcSEcCtD
Mitoxantrone—Sweating—Methotrexate—systemic scleroderma	0.000214	0.000652	CcSEcCtD
Mitoxantrone—Haematuria—Methotrexate—systemic scleroderma	0.000213	0.000649	CcSEcCtD
Mitoxantrone—Vomiting—Leflunomide—systemic scleroderma	0.000213	0.000647	CcSEcCtD
Mitoxantrone—Alopecia—Prednisone—systemic scleroderma	0.000212	0.000646	CcSEcCtD
Mitoxantrone—Hypersensitivity—Lisinopril—systemic scleroderma	0.000212	0.000644	CcSEcCtD
Mitoxantrone—Rash—Leflunomide—systemic scleroderma	0.000211	0.000642	CcSEcCtD
Mitoxantrone—Dermatitis—Leflunomide—systemic scleroderma	0.000211	0.000641	CcSEcCtD
Mitoxantrone—Nausea—Azathioprine—systemic scleroderma	0.00021	0.00064	CcSEcCtD
Mitoxantrone—Headache—Leflunomide—systemic scleroderma	0.000209	0.000637	CcSEcCtD
Mitoxantrone—Erythema—Prednisone—systemic scleroderma	0.000209	0.000636	CcSEcCtD
Mitoxantrone—Agranulocytosis—Methotrexate—systemic scleroderma	0.000209	0.000635	CcSEcCtD
Mitoxantrone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000207	0.000631	CcSEcCtD
Mitoxantrone—Asthenia—Lisinopril—systemic scleroderma	0.000206	0.000627	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000206	0.000626	CcSEcCtD
Mitoxantrone—Vomiting—Mycophenolic acid—systemic scleroderma	0.000203	0.000617	CcSEcCtD
Mitoxantrone—Haemoglobin—Methotrexate—systemic scleroderma	0.000202	0.000614	CcSEcCtD
Mitoxantrone—Rash—Mycophenolic acid—systemic scleroderma	0.000201	0.000612	CcSEcCtD
Mitoxantrone—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000201	0.000611	CcSEcCtD
Mitoxantrone—Haemorrhage—Methotrexate—systemic scleroderma	0.000201	0.000611	CcSEcCtD
Mitoxantrone—Hepatitis—Methotrexate—systemic scleroderma	0.000201	0.000611	CcSEcCtD
Mitoxantrone—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000609	CcSEcCtD
Mitoxantrone—Headache—Mycophenolic acid—systemic scleroderma	0.0002	0.000608	CcSEcCtD
Mitoxantrone—Pharyngitis—Methotrexate—systemic scleroderma	0.000199	0.000606	CcSEcCtD
Mitoxantrone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000199	0.000606	CcSEcCtD
Mitoxantrone—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000199	0.000606	CcSEcCtD
Mitoxantrone—Nausea—Leflunomide—systemic scleroderma	0.000199	0.000604	CcSEcCtD
Mitoxantrone—Vision blurred—Prednisone—systemic scleroderma	0.000197	0.0006	CcSEcCtD
Mitoxantrone—Diarrhoea—Lisinopril—systemic scleroderma	0.000197	0.000598	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Prednisone—systemic scleroderma	0.000194	0.00059	CcSEcCtD
Mitoxantrone—Anaemia—Prednisone—systemic scleroderma	0.000193	0.000588	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CENPC—systemic scleroderma	0.00019	0.00972	CbGpPWpGaD
Mitoxantrone—Nausea—Mycophenolic acid—systemic scleroderma	0.000189	0.000577	CcSEcCtD
Mitoxantrone—Malaise—Prednisone—systemic scleroderma	0.000188	0.000574	CcSEcCtD
Mitoxantrone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000185	0.000564	CcSEcCtD
Mitoxantrone—Vomiting—Lisinopril—systemic scleroderma	0.000183	0.000556	CcSEcCtD
Mitoxantrone—Rash—Lisinopril—systemic scleroderma	0.000181	0.000551	CcSEcCtD
Mitoxantrone—Convulsion—Prednisone—systemic scleroderma	0.000181	0.000551	CcSEcCtD
Mitoxantrone—Dermatitis—Lisinopril—systemic scleroderma	0.000181	0.000551	CcSEcCtD
Mitoxantrone—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000181	0.00055	CcSEcCtD
Mitoxantrone—Hypertension—Prednisone—systemic scleroderma	0.00018	0.000549	CcSEcCtD
Mitoxantrone—Chills—Methotrexate—systemic scleroderma	0.00018	0.000548	CcSEcCtD
Mitoxantrone—Headache—Lisinopril—systemic scleroderma	0.00018	0.000548	CcSEcCtD
Mitoxantrone—Arthralgia—Prednisone—systemic scleroderma	0.000178	0.000542	CcSEcCtD
Mitoxantrone—Myalgia—Prednisone—systemic scleroderma	0.000178	0.000542	CcSEcCtD
Mitoxantrone—Anxiety—Prednisone—systemic scleroderma	0.000177	0.00054	CcSEcCtD
Mitoxantrone—Alopecia—Methotrexate—systemic scleroderma	0.000177	0.00054	CcSEcCtD
Mitoxantrone—Discomfort—Prednisone—systemic scleroderma	0.000176	0.000535	CcSEcCtD
Mitoxantrone—Erythema—Methotrexate—systemic scleroderma	0.000175	0.000532	CcSEcCtD
Mitoxantrone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000172	0.000524	CcSEcCtD
Mitoxantrone—Dysgeusia—Methotrexate—systemic scleroderma	0.000171	0.000521	CcSEcCtD
Mitoxantrone—Nausea—Lisinopril—systemic scleroderma	0.000171	0.000519	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Prednisone—systemic scleroderma	0.000171	0.000519	CcSEcCtD
Mitoxantrone—Oedema—Prednisone—systemic scleroderma	0.000171	0.000519	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—CENPC—systemic scleroderma	0.00017	0.00869	CbGpPWpGaD
Mitoxantrone—Infection—Prednisone—systemic scleroderma	0.000169	0.000516	CcSEcCtD
Mitoxantrone—Back pain—Methotrexate—systemic scleroderma	0.000169	0.000514	CcSEcCtD
Mitoxantrone—Shock—Prednisone—systemic scleroderma	0.000168	0.000511	CcSEcCtD
Mitoxantrone—Tachycardia—Prednisone—systemic scleroderma	0.000166	0.000507	CcSEcCtD
Mitoxantrone—Skin disorder—Prednisone—systemic scleroderma	0.000166	0.000504	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Prednisone—systemic scleroderma	0.000165	0.000502	CcSEcCtD
Mitoxantrone—Vision blurred—Methotrexate—systemic scleroderma	0.000165	0.000501	CcSEcCtD
Mitoxantrone—Anorexia—Prednisone—systemic scleroderma	0.000163	0.000495	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000162	0.000493	CcSEcCtD
Mitoxantrone—Anaemia—Methotrexate—systemic scleroderma	0.000161	0.000491	CcSEcCtD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.00016	0.00821	CbGpPWpGaD
Mitoxantrone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00016	0.000487	CcSEcCtD
Mitoxantrone—Rash—Mycophenolate mofetil—systemic scleroderma	0.000159	0.000483	CcSEcCtD
Mitoxantrone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000159	0.000483	CcSEcCtD
Mitoxantrone—Headache—Mycophenolate mofetil—systemic scleroderma	0.000158	0.00048	CcSEcCtD
Mitoxantrone—Malaise—Methotrexate—systemic scleroderma	0.000158	0.000479	CcSEcCtD
Mitoxantrone—Leukopenia—Methotrexate—systemic scleroderma	0.000156	0.000476	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000155	0.000473	CcSEcCtD
Mitoxantrone—Paraesthesia—Prednisone—systemic scleroderma	0.000153	0.000466	CcSEcCtD
Mitoxantrone—Cough—Methotrexate—systemic scleroderma	0.000152	0.000464	CcSEcCtD
Mitoxantrone—Convulsion—Methotrexate—systemic scleroderma	0.000151	0.000461	CcSEcCtD
Mitoxantrone—Dyspepsia—Prednisone—systemic scleroderma	0.00015	0.000457	CcSEcCtD
Mitoxantrone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000149	0.000455	CcSEcCtD
Mitoxantrone—Chest pain—Methotrexate—systemic scleroderma	0.000149	0.000453	CcSEcCtD
Mitoxantrone—Arthralgia—Methotrexate—systemic scleroderma	0.000149	0.000453	CcSEcCtD
Mitoxantrone—Myalgia—Methotrexate—systemic scleroderma	0.000149	0.000453	CcSEcCtD
Mitoxantrone—Decreased appetite—Prednisone—systemic scleroderma	0.000148	0.000451	CcSEcCtD
Mitoxantrone—Fatigue—Prednisone—systemic scleroderma	0.000147	0.000448	CcSEcCtD
Mitoxantrone—Discomfort—Methotrexate—systemic scleroderma	0.000147	0.000447	CcSEcCtD
Mitoxantrone—Constipation—Prednisone—systemic scleroderma	0.000146	0.000444	CcSEcCtD
Mitoxantrone—Confusional state—Methotrexate—systemic scleroderma	0.000144	0.000438	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000143	0.000434	CcSEcCtD
Mitoxantrone—Infection—Methotrexate—systemic scleroderma	0.000142	0.000431	CcSEcCtD
Mitoxantrone—Feeling abnormal—Prednisone—systemic scleroderma	0.000141	0.000428	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Methotrexate—systemic scleroderma	0.00014	0.000425	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000139	0.000425	CcSEcCtD
Mitoxantrone—Skin disorder—Methotrexate—systemic scleroderma	0.000138	0.000421	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000138	0.000419	CcSEcCtD
Mitoxantrone—Anorexia—Methotrexate—systemic scleroderma	0.000136	0.000414	CcSEcCtD
Mitoxantrone—Urticaria—Prednisone—systemic scleroderma	0.000136	0.000412	CcSEcCtD
Mitoxantrone—Body temperature increased—Prednisone—systemic scleroderma	0.000135	0.00041	CcSEcCtD
Mitoxantrone—Abdominal pain—Prednisone—systemic scleroderma	0.000135	0.00041	CcSEcCtD
Mitoxantrone—Hypotension—Methotrexate—systemic scleroderma	0.000133	0.000405	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.00013	0.000395	CcSEcCtD
Mitoxantrone—Paraesthesia—Methotrexate—systemic scleroderma	0.000128	0.00039	CcSEcCtD
Mitoxantrone—Dyspnoea—Methotrexate—systemic scleroderma	0.000127	0.000387	CcSEcCtD
Mitoxantrone—Somnolence—Methotrexate—systemic scleroderma	0.000127	0.000386	CcSEcCtD
Mitoxantrone—Hypersensitivity—Prednisone—systemic scleroderma	0.000126	0.000383	CcSEcCtD
Mitoxantrone—Dyspepsia—Methotrexate—systemic scleroderma	0.000125	0.000382	CcSEcCtD
Mitoxantrone—Decreased appetite—Methotrexate—systemic scleroderma	0.000124	0.000377	CcSEcCtD
Mitoxantrone—Fatigue—Methotrexate—systemic scleroderma	0.000123	0.000374	CcSEcCtD
Mitoxantrone—Asthenia—Prednisone—systemic scleroderma	0.000122	0.000373	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—CSK—systemic scleroderma	0.000122	0.00627	CbGpPWpGaD
Mitoxantrone—Pain—Methotrexate—systemic scleroderma	0.000122	0.000371	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000122	0.00624	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CENPA—systemic scleroderma	0.00012	0.00617	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—ITGAM—systemic scleroderma	0.00012	0.00613	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—CD247—systemic scleroderma	0.00012	0.00613	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.000119	0.00607	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Methotrexate—systemic scleroderma	0.000117	0.000358	CcSEcCtD
Mitoxantrone—Diarrhoea—Prednisone—systemic scleroderma	0.000117	0.000355	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000117	0.000355	CcSEcCtD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000116	0.00592	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CD247—systemic scleroderma	0.000115	0.00589	CbGpPWpGaD
Mitoxantrone—Urticaria—Methotrexate—systemic scleroderma	0.000113	0.000345	CcSEcCtD
Mitoxantrone—Body temperature increased—Methotrexate—systemic scleroderma	0.000113	0.000343	CcSEcCtD
Mitoxantrone—Abdominal pain—Methotrexate—systemic scleroderma	0.000113	0.000343	CcSEcCtD
Mitoxantrone—BTK—Innate Immune System—TNFAIP3—systemic scleroderma	0.000112	0.00574	CbGpPWpGaD
Mitoxantrone—Vomiting—Prednisone—systemic scleroderma	0.000108	0.00033	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—CENPA—systemic scleroderma	0.000108	0.00552	CbGpPWpGaD
Mitoxantrone—Rash—Prednisone—systemic scleroderma	0.000108	0.000327	CcSEcCtD
Mitoxantrone—Dermatitis—Prednisone—systemic scleroderma	0.000107	0.000327	CcSEcCtD
Mitoxantrone—Headache—Prednisone—systemic scleroderma	0.000107	0.000325	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—BLK—systemic scleroderma	0.000106	0.00545	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000105	0.00539	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Methotrexate—systemic scleroderma	0.000105	0.00032	CcSEcCtD
Mitoxantrone—Asthenia—Methotrexate—systemic scleroderma	0.000102	0.000311	CcSEcCtD
Mitoxantrone—Nausea—Prednisone—systemic scleroderma	0.000101	0.000308	CcSEcCtD
Mitoxantrone—Diarrhoea—Methotrexate—systemic scleroderma	9.75e-05	0.000297	CcSEcCtD
Mitoxantrone—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	9.54e-05	0.00488	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	9.47e-05	0.00485	CbGpPWpGaD
Mitoxantrone—Vomiting—Methotrexate—systemic scleroderma	9.06e-05	0.000276	CcSEcCtD
Mitoxantrone—Rash—Methotrexate—systemic scleroderma	8.99e-05	0.000274	CcSEcCtD
Mitoxantrone—Dermatitis—Methotrexate—systemic scleroderma	8.98e-05	0.000273	CcSEcCtD
Mitoxantrone—Headache—Methotrexate—systemic scleroderma	8.93e-05	0.000272	CcSEcCtD
Mitoxantrone—BTK—Adaptive Immune System—CTLA4—systemic scleroderma	8.72e-05	0.00446	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	8.66e-05	0.00444	CbGpPWpGaD
Mitoxantrone—Nausea—Methotrexate—systemic scleroderma	8.47e-05	0.000258	CcSEcCtD
Mitoxantrone—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	7.85e-05	0.00402	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	7.46e-05	0.00382	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CSK—systemic scleroderma	7.42e-05	0.0038	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	7.42e-05	0.0038	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IRF5—systemic scleroderma	7.3e-05	0.00374	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	7.18e-05	0.00368	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IRF8—systemic scleroderma	6.98e-05	0.00357	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—ITGAM—systemic scleroderma	6.98e-05	0.00357	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CD247—systemic scleroderma	6.98e-05	0.00357	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CD40LG—systemic scleroderma	6.78e-05	0.00347	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—TNFAIP3—systemic scleroderma	6.53e-05	0.00335	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—BLK—systemic scleroderma	6.45e-05	0.00331	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6e-05	0.00307	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.81e-05	0.00297	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CTLA4—systemic scleroderma	5.29e-05	0.00271	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.55e-05	0.00233	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.53e-05	0.00232	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.4e-05	0.00225	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—SMAD7—systemic scleroderma	4.38e-05	0.00224	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—HLA-DQB1—systemic scleroderma	4.35e-05	0.00223	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IL1A—systemic scleroderma	4.13e-05	0.00212	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CD40LG—systemic scleroderma	4.11e-05	0.00211	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TGFBI—systemic scleroderma	4e-05	0.00205	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	3.89e-05	0.00199	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HSPG2—systemic scleroderma	3.19e-05	0.00163	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CSK—systemic scleroderma	3.08e-05	0.00158	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	3.02e-05	0.00155	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CD247—systemic scleroderma	2.9e-05	0.00148	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—HSPG2—systemic scleroderma	2.67e-05	0.00137	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—HSPG2—systemic scleroderma	2.59e-05	0.00132	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—HSPG2—systemic scleroderma	2.35e-05	0.0012	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IL1B—systemic scleroderma	2.16e-05	0.0011	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—CTGF—systemic scleroderma	2.03e-05	0.00104	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CTGF—systemic scleroderma	1.96e-05	0.001	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—CTGF—systemic scleroderma	1.78e-05	0.000913	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—HSPG2—systemic scleroderma	1.69e-05	0.000865	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.49e-05	0.000764	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CTGF—systemic scleroderma	1.28e-05	0.000656	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.27e-05	0.000651	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NOS3—systemic scleroderma	1.05e-05	0.000539	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CTGF—systemic scleroderma	9.64e-06	0.000494	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—NOS3—systemic scleroderma	8.82e-06	0.000452	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—NOS3—systemic scleroderma	8.53e-06	0.000437	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—HSPG2—systemic scleroderma	7.83e-06	0.000401	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—NOS3—systemic scleroderma	7.76e-06	0.000397	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TGFB1—systemic scleroderma	6.96e-06	0.000357	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CTGF—systemic scleroderma	5.94e-06	0.000304	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—NOS3—systemic scleroderma	5.57e-06	0.000285	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NOS3—systemic scleroderma	4.19e-06	0.000215	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NOS3—systemic scleroderma	2.58e-06	0.000132	CbGpPWpGaD
